Ticker brief
VIR
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
23
authors 14d
15
crowd 14d
-0.8σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-15 · now +0.45 (−1 bearish … +1 bullish)
Who spoke15
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OptionsFlowBoss | C | · | 3 | +0.22 |
| @OzmosiHealth | C | · | 3 | +0.17 |
| @semodough | C | -1.06 | 3 | +0.35 |
| @Biotech2k1 | A | +1.11 | 2 | -0.38 |
| @BioStocks | C | -1.77 | 2 | +0.50 |
| @Greatstockpix | C | -1.40 | 1 | +0.00 |
| @IPODave | B | -0.45 | 1 | -0.15 |
| @kiantrades | C | -1.01 | 1 | +0.35 |
| @zohmbastic | C | -2.94 | 1 | +0.50 |
| @CHItrader | B | -0.22 | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.45 |
| @FierceBiotech | A | -0.83 | 1 | +0.35 |
| @ElliottWaveSage | C | +0.28 | 1 | +0.50 |
| @fwpharma | B | -1.91 | 1 | +0.50 |
| @JackPrescottX | C | -0.16 | 1 | +0.50 |
Recent signals23of 23 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @JackPrescottX | +0.50 | Vir and Gilead entered a multi-program oncology collaboration with substantial milestone economics. | · | tweet ↗ |
| 2026-10-15 | @semodough | +0.40 | Morgan Stanley sets a $25 target and highlights a new collaboration, catalysts and $1.01B cash. | · | tweet ↗ |
| 2026-10-14 | @fwpharma | +0.50 | Gilead and Vir entered a $1.9B T-cell-engager pact for solid tumors. | · | tweet ↗ |
| 2026-10-14 | @ElliottWaveSage | +0.50 | Vir and Gilead signed a three-program cancer deal with upfront and milestone payments. | · | tweet ↗ |
| 2026-10-14 | @FierceBiotech | +0.35 | Gilead licensed Vir Biotechnology's T-cell engager technology in a potential $1.9B deal. | · | tweet ↗ |
| 2026-10-14 | @OpenOutcrier | +0.45 | Vir Biotechnology and Gilead announced a solid-tumor drug deal. | · | tweet ↗ |
| 2026-10-14 | @CHItrader | +0.50 | Gilead agreed to pay up to $1.875B for three Vir cancer drug candidates. | · | tweet ↗ |
| 2026-10-14 | @zohmbastic | +0.50 | Vir and Gilead signed a multi-program oncology collaboration worth up to $1.875B plus royalties. | · | tweet ↗ |
| 2026-10-14 | @BioStocks | +0.50 | Reports a VIR-GILD oncology collaboration with $90 million upfront and a premium equity investment. | · | tweet ↗ |
| 2026-10-09 | @semodough | +0.40 | Needham sees 20-40% upside to about $15 and models $1.3B of non-risk-adjusted peak sales. | · | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.50 | FDA granted Fast Track designation to VIR-5500 for prostate cancer. | · | tweet ↗ |
| 2026-10-08 | @semodough | +0.25 | Models VIR's annual mCRPC patient pool growing from about 40,000 in 2025 to 83,000 by 2040. | · | tweet ↗ |
| 2026-10-08 | @BioStocks | +0.50 | FDA grants Fast Track designation to VIR-5500 for metastatic castration-resistant prostate cancer. | · | tweet ↗ |
| 2026-10-06 | @OzmosiHealth | +0.00 | Vir schedules Phase 2 tobevibart hepatitis-D results for 2026-11-08. | · | tweet ↗ |
| 2026-10-06 | @OzmosiHealth | +0.00 | Vir schedules Phase 2 elebsiran hepatitis-D results for 2026-11-08. | · | tweet ↗ |
| 2026-10-06 | @Biotech2k1 | -0.40 | Argues VIR's siRNA combination adds toxicity and monitoring burden. | · | tweet ↗ |
| 2026-10-06 | @OptionsFlowBoss | +0.00 | Reports open-interest changes, with details contained in linked media. | · | tweet ↗ |
| 2026-10-06 | @Biotech2k1 | -0.35 | Questions VIR's best-in-class claim by contrasting combo efficacy with MIRM monotherapy. | · | tweet ↗ |
| 2026-10-05 | @kiantrades | +0.35 | Reports notable bullish and bearish options flow with strikes, expiries and premiums. | · | tweet ↗ |
| 2026-10-05 | @IPODave | -0.15 | Expresses suspicion about the timing of VIR and MRNA IPOs before Covid while noting their correlated run. | · | tweet ↗ |
| 2026-10-05 | @Greatstockpix | +0.00 | Daily watchlist video lists numerous tickers without specific entry intent; first six retained. | · | tweet ↗ |
| 2026-10-05 | @OptionsFlowBoss | +0.00 | References VIR gamma heat zones in a chart. | · | tweet ↗ |
| 2026-10-05 | @OptionsFlowBoss | +0.65 | Reports a $203K VIR call buyer. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.